Alecinix

Alectinib (Alecensa) instructions

Common name: Alectinib

Trade name: Alecensa

All names: Alectinib, Alectinib, Alectinib, Alectinib, Alectinib, Alecensa, LuciAlect, Alecinix, Alecnib

Alectinib indications

Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer

Alectinib dosage and administration

600 mg orally 2 times daily. Giving with food.

Alectinib Warnings and Precautions

⑴ Hepatotoxicity: Monitor liver laboratory tests every 2 weeks during the first 2 months of treatment, and periodically during any treatment period. In cases of severe ALT, AST, or bilirubin elevations, withhold, then reduce dose, or permanently discontinue ALECENSA.

⑵Interstitial lung disease (ILD)/pneumonia: occurs in 0.4% of patients. Withhold ALECENSA immediately in patients diagnosed with ILD/pneumonitis and permanently discontinue if no other underlying cause of ILD/pneumonitis has been determined.

⑶Bradycardia: Monitor heart rate and blood pressure regularly. If symptomatic, withhold ALECENSA and reduce dose, or permanently discontinue.

⑷ Severe myalgia and elevated creatine phosphokinase (CPK): occurred in 1.2% and 4.6% of patients respectively. Assess CPK every 2 weeks during the first month of treatment and when patients report myalgia, tenderness, or weakness. In cases of severe CPK elevation, withhold and then resume or reduce dose.

⑸Embryo-fetal toxicity: ALECENSA may cause fetal harm. Advise females of reproductive potential of the potential risks to the fetus and to use effective contraception.

Adverse reactions of alectinib

The most common adverse reactions (incidence ≥20%) are fatigue, constipation, edema and myalgia.

Alectinib is used in special populations

Breastfeeding: Do not breastfeed.